On late 27 April, Fosun Pharma released its Q1 result, which demonstrated a sound performance.

In the first quarter of 2017, Fosun Pharma recorded an operating revenue of RMB3.88 billion, representing an increase of 20.29% year on year; net profit attributable to equity holders of Fosun Pharma was RMB738 million, representing an increase of 16.32% year on year; net profit attributable to equity holders of the Company after deduction of non-recurring profit or loss was RMB518 million, representing an increase of 20.05% year on year.

The investment in R&D kept increasing, recording RMB198 million from January to March, 2017, an increase of 37.64% compared to the same period last year.

Besides, in order to further integrate the internal segments, it withdrawn the “Pharmaceutical Industry Management Committee” and “Healthcare Service Management Committee” while“ Fosun Pharmaceutical Industrial” and “Fosun Hospital Investment” undertook the functions of the two committees respectively. It also merged “Medical Devices Division” and “Medical Diagnosis Division”while setting up the new “Medical Technology Management Committee”, which is in charge of medical devices and medical diagnosis business, aiming to achieve internal resource integration and accelerate the development of the Company.

Fosun Pharma says, it will carry forward the developing strategy of "organic growth, external expansion and integrated development", seize the opportunities of pharmaceutical industry and healthcare services. At the same time, it will keep focusing on R&D investment, further strengthening its core competitiveness by integrating internal resources.